Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI, Inc. (OTCQX: PYNKF) is a commercial-stage medical technology company whose news flow centers on the development, clinical use, and commercialization of its optical coherence tomography (OCT) imaging platforms for cancer surgery. Company updates frequently highlight the adoption of its FDA-cleared Perimeter S-Series OCT system in operating rooms across the United States, including agreements with major health systems and hospitals for tissue visualization during surgery.
News releases describe how surgeons at leading centers are using the S-Series OCT to obtain real-time, cross-sectional visualization of excised tissues at the cellular level, and how this imaging can provide additional insights for intraoperative decision-making. Perimeter also reports on progress with its investigational Perimeter B-Series OCT with Assist AI, a breakthrough-device-designated platform that combines OCT with artificial intelligence and has been evaluated in a pivotal clinical trial supported by a grant from the Cancer Prevention and Research Institute of Texas.
Investors following PYNKF can expect updates on commercial traction for the S-Series, including new hospital installations and systemwide agreements, as well as regulatory milestones related to the B-Series PMA review. The company’s news also covers participation in professional medical conferences, breast surgery forums, and investor events, along with capital raising activities intended to support commercialization and product development.
This news page aggregates Perimeter’s press releases and related coverage so readers can monitor developments in its OCT imaging technology, clinical collaborations, regulatory pathway, and corporate strategy. For those tracking small- and micro-cap medical technology names, the PYNKF news feed offers ongoing insight into how Perimeter is positioning its imaging platforms within cancer surgery and breast care.
Perimeter Medical Imaging AI, a commercial-stage medical technology company, announced its AI technology is featured in the "Artificial Intelligence: Your Mind & The Machine" exhibit at the Museum of Science & History (MoSH) in Memphis, TN, running until May 6, 2023. The company’s CEO, Jeremy Sobotta, emphasized the significance of their next-gen ultra-high resolution optical imaging technology being evaluated in clinical trials at the West Cancer Center. Supported by AI industry leaders, Perimeter aims to enhance surgical decision-making for cancer patients. The company’s innovative imaging systems are FDA-cleared and are backed by a grant of up to $7.4 million from the Cancer Prevention and Research Institute of Texas.
Perimeter Medical Imaging AI (PYNKF) announced significant leadership changes, appointing Suzanne Foster as the new Chair of the Board of Directors. Effective immediately, her extensive background in healthcare will enhance the company's mission in cancer surgery technology. CEO Jeremy Sobotta expressed confidence in Foster's leadership, praising her experience within the organization. Former Chair Dr. Anthony Holler remains as a director. Additionally, Chris Scott resigned as CFO, with Russell Wagner stepping in as Interim CFO while a search for Scott’s replacement begins. Perimeter aims to leverage its advanced imaging technology to improve patient outcomes.
Perimeter Medical Imaging AI (TSX-V: PINK, OTC: PYNKF) announced the completion of two additional installations of its S-Series OCT system at the end of 2022, successfully doubling its commercial installed base during Q4. CEO Jeremy Sobotta emphasized the momentum in their business, particularly within a major healthcare system, enhancing the value perceived by early users. This expansion aims to improve patient outcomes and reduce healthcare costs in the U.S.
Perimeter Medical Imaging AI (PYNKF) announced a peer-reviewed study published in JAMA Otolaryngology—Head and Neck Surgery validating its wide-field Optical Coherence Tomography (WF-OCT) technology for real-time margin visualization in head and neck surgeries. The study involved 53 patients with squamous cell carcinoma, demonstrating that WF-OCT can potentially improve surgical outcomes without disrupting existing workflows. CEO Jeremy Sobotta highlighted the importance of this innovative imaging technology, which correlates well with histological results.
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK, OTC: PYNKF) announced its third-quarter financial results for 2022, highlighting key developments in its clinical trials and commercial placements. The company activated eight clinical trial sites for its B-Series OCT system with ImgAssist AI and received FDA approval for further expansion. Operating expenses rose to $5.94 million, while the net loss improved to $818,527 compared to $3.88 million in Q3 2021. Cash and cash equivalents stood at $43.2 million as of September 30, 2022.
CEO Jeremy Sobotta expressed optimism regarding ongoing trials and commercial adoption amid challenging conditions.
Perimeter Medical Imaging AI, Inc. (PYNKF) announced a successful commercial placement of its Perimeter S-Series OCT system at a second hospital within a major healthcare network in North Texas. This follows a prior placement within the same network and underscores Perimeter's strategy to expand its technology in integrated delivery systems. CEO Jeremy Sobotta highlighted positive feedback from end-users and stakeholders, indicating strong market validation for their advanced imaging tools aimed at transforming cancer surgery.
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK, OTC: PYNKF) will announce its Q3 2022 financial results on November 15, 2022, after U.S. market close. A conference call is scheduled for the same day at 5:00 PM ET, featuring CEO Jeremy Sobotta and CFO Chris Scott. The call will be accessible via dial-in and webcast, with details available on the Company's website. Perimeter focuses on innovative imaging solutions for cancer surgery, aiming to enhance surgical outcomes.
Perimeter Medical Imaging AI, Inc. (PYNKF) announces the results of its 2022 annual and special meeting of shareholders held on October 27, 2022. Shareholders approved all matters, including the election of seven board members and a new omnibus equity incentive plan. The Omnibus Plan allows the issuance of options and units, capping at 12,834,531 common shares. Additionally, KPMG LLP was reappointed as the company’s auditor for the upcoming year. Perimeter focuses on innovative imaging tools to enhance cancer surgery, with promising products currently in evaluation.
Perimeter Medical Imaging AI (OTC:PYNKF) announced significant findings at the College of American Pathologists Annual Meeting 2022. Their research highlights the use of the Perimeter S-Series Wide-Field Optical Coherence Tomography (OCT) system for real-time microstructural imaging across various tissues, including breast, kidney, and lung. Presentations addressed the intraoperative evaluation of tissue in head and neck surgery, supporting the device's potential to enhance surgical outcomes. The device offers 10x greater resolution than X-ray and 100x that of MRI, aligning with the company's mission to improve cancer surgery.
Perimeter Medical Imaging AI announced its graduation from a Tier 2 Issuer to a Tier 1 Issuer on the TSX Venture Exchange, effective October 5, 2022. This upgrade reflects the Company’s significant financial resources and sustainable business model, with cash and cash equivalents totaling $44,966,273 as of June 30, 2022. The transition allows for the release of 5,080,959 shares from escrow, better positioning Perimeter for growth in the medical imaging sector.
FAQ
What is the current stock price of Perimeter Medical Imaging Ai (PYNKF)?
What is the market cap of Perimeter Medical Imaging Ai (PYNKF)?
